---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-098861"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:28:01.945808+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharmaceuticals appoints Winston Kung to Board, replaces exiting director Chip Catlin

## Summary
- Avery 'Chip' Catlin resigned from Board and as Audit Chair effective Aug 15, 2024; no disagreement with company.
- Winston W. Kung, age 49, appointed to Board effective Aug 16, 2024; will serve as Audit Committee Chair.
- Kung is CFO of ArriVent BioPharma; previously COO/CFO at PMV Pharma, VP at Celgene, and roles at Citigroup and Lehman.
- Kung receives initial option grant for 5,566 shares and 5,566 RSUs; annual cash retainer $40,000 plus $20,000 for Audit Chair.

## SEC filing metadata
- accession: 0000950170-24-098861
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/0000950170-24-098861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/crbp-20240815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-098861
- JSON: https://secwatch.observer/filing/0000950170-24-098861.json
- Plain text: https://secwatch.observer/filing/0000950170-24-098861.txt

## Key facts
- Executive change
  Winston W. Kung was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective August 16, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Winston W. Kung, age 49, to serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/0000950170-24-098861-index.htm
- Executive change
  Avery W. Catlin resigned as Director at Corbus Pharmaceuticals Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On August 15, 2024, Avery W. Catlin submitted his resignation from the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), effective as of August 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017024098861/0000950170-24-098861-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.